Compare HLNE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLNE | DNTH |
|---|---|---|
| Founded | 1991 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.6B |
| IPO Year | 2017 | 2018 |
| Metric | HLNE | DNTH |
|---|---|---|
| Price | $80.57 | $84.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $156.78 | $121.00 |
| AVG Volume (30 Days) | ★ 859.4K | 502.6K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.44% | N/A |
| EPS Growth | ★ 41.64 | N/A |
| EPS | ★ 3.98 | N/A |
| Revenue | ★ $758,993,000.00 | $2,036,000.00 |
| Revenue This Year | $9.69 | N/A |
| Revenue Next Year | $15.81 | $29.48 |
| P/E Ratio | $20.31 | ★ N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $76.79 | $16.77 |
| 52 Week High | $161.13 | $96.50 |
| Indicator | HLNE | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 32.30 | 44.17 |
| Support Level | N/A | $79.27 |
| Resistance Level | $93.52 | $90.23 |
| Average True Range (ATR) | 3.70 | 4.80 |
| MACD | -0.11 | -0.48 |
| Stochastic Oscillator | 16.62 | 25.47 |
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.